Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
15 participants
INTERVENTIONAL
2006-07-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study
NCT00708396
The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia
NCT00148447
Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)
NCT00229385
Minocycline for the Treatment of Early-Phase Schizophrenia
NCT00733057
Psilocybin for Treatment of OCD-2
NCT06992999
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Escitalopram
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Serious medical condintions,
* Being on SSRI treatment
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lundbeck Israel
INDUSTRY
BeerYaakov Mental Health Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Beer-Yaakov MHC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rafael Octavio Stryjer, M.D.
Role: PRINCIPAL_INVESTIGATOR
Beer Yaakov Mental Health Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beer Yaakov MHC
Beer Yaakov, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Escitalopram-173CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.